Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02338960 · ClinicalTrials.gov registry record · Phase 3
2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder
A Phase 3 study of Hypoactive Sexual Desire Disorder, sponsored by Palatin Technologies.
- Completed
- Registry status
- Phase 3
- Development phase
- 714
- Enrollment target
- 20
- Study locations
NCT02338960: Completed Phase 3 study of Hypoactive Sexual Desire Disorder, sponsored by Palatin Technologies.
NCT02338960 is a Phase 3 study of Hypoactive Sexual Desire Disorder that has completed, run by Palatin Technologies. The registered enrollment target is 714 participants, above the 315-participant average among 8 other Hypoactive Sexual Desire Disorder trials with a reported enrollment target (127% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02338960, a Phase 3 study of Hypoactive Sexual Desire Disorder, has completed, sponsored by Palatin Technologies.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 714 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an optional Open-label Extension to evaluate the efficacy of bremelanotide (BMT), administered subcutaneously (SC) on an as needed basis for the treatment of HSDD (with or without decreased arousal) in premenopausal females.
Primary Outcome
As measured by change from baseline to end-of-study in the desire domain from the FSFI (Question Q1 and Q2), 28-day recall, co-primary endpoint - FSFI desire domain This score is on a scale ranging from 1.2 to 6. A higher score on this scale represent an increase in sexual desire and is a better outcome.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Bremelanotide
Study Locations (20)
California
- Palatin Clinical Site 258 - Beverly Hills
- Palatin Clinical Site 256 - Garden Grove
- Palatin Clinical Site 291 - Los Angeles
- Palatin Clinical Site 270 - Oakland
- Palatin Clinical Site 210 - San Diego
- Palatin Clinical Site 251 - San Diego
- Palatin Clinical Site 272 - Sherman Oaks
- Palatin Clinical Site 253 - Tarzana
Colorado
- Palatin Clinical Site 212 - Denver
- Palatin Clinical Site 219 - Denver
- Palatin Clinical Site 243 - Lakewood
Arizona
- Palatin Clinical Site 218 - Phoenix
- Palatin Clinical Site 254 - Tucson
Connecticut
- Palatin Clinical Site 211 - New London
- Palatin Clinical Site 229 - Waterbury
Florida
- Palatin Clinical Site 204 - Aventura
- Palatin Clinical Site 273 - Coral Gables
Alabama
- Palatin Clinical Site 242 - Birmingham
Arkansas
- Palatin Clinical Site 207 - Hot Springs
District of Columbia
- Palatin Clinical Site 202 - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 714 participants |
| Start Date | 2015-01 |
| Est. Completion | 2017-06-29 |
| Phase | Phase 3 |
What the finished NCT02338960 record still lists
NCT02338960 is an interventional study that assigns participants to a tested intervention. The registered 714 participants enrollment target is mid-sized for trials with a published cap, above the 315-participant average among 8 other Hypoactive Sexual Desire Disorder trials with a reported enrollment target (127% higher).
The record links to 1 condition, with Hypoactive Sexual Desire Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02338960 names 20 study sites across 8 states, led by California, Colorado, Arizona.
Frequently Asked Questions
What is clinical trial NCT02338960 about?
NCT02338960 is a clinical study titled "2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder". A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an optional Open-label Extension to evaluate the efficacy of bremelanotide (BMT), administered subcutaneously (SC) on an as needed basis for the treatment of HSDD (with or without decreased arousal) in premenopausal f...
What is the current status of trial NCT02338960?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 714 participants. The study started on 2015-01. Estimated completion is 2017-06-29.
What conditions does trial NCT02338960 study?
This clinical trial studies the following conditions: Hypoactive Sexual Desire Disorder.
What interventions are being tested in trial NCT02338960?
The interventions under investigation include: Placebo (DRUG), Bremelanotide (DRUG).
Who is sponsoring clinical trial NCT02338960?
This trial is sponsored by Palatin Technologies, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02338960 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypoactive Sexual Desire Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02338960's enrollment target sits among peer trials
714 1st of 8 higher than 8 of 8 other Hypoactive Sexual Desire Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypoactive Sexual Desire Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
COMPLETED · Phase 3
-
Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
COMPLETED · Phase 3
-
Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)
COMPLETED · Phase 3
-
Lybridos in Pre-and Postmenopausal Women With Hypoactive Sexual Desire Disorder
COMPLETED · Phase 2
-
A Mindfulness-based Intervention for Older Women With Low Sexual Desire
COMPLETED · NA
-
Lybridos in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder Due to Maladaptive Activation of Sexual Inhibitory Systems
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05208762 · 714 participants · Phase 1
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- NCT06758401 · 714 participants · Phase 3
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- NCT04680000 · 716 participants · NA
Chronic Pain Management In Primary Care Using Behavioral Health Consultants
- NCT06179160 · 710 participants · Phase 1
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia